Free Trial

Conduit Pharmaceuticals Q4 2024 Earnings Report

Conduit Pharmaceuticals logo
$0.75 +0.02 (+3.43%)
As of 04:00 PM Eastern

Conduit Pharmaceuticals EPS Results

Actual EPS
-$20.33
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Conduit Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conduit Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
After Market Closes

Conference Call Resources

Remove Ads

Conduit Pharmaceuticals Earnings Headlines

Conduit Pharmaceuticals receives U.S. patent approval for AZD1656
Trump… a socialist?
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Conduit Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Conduit Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Conduit Pharmaceuticals and other key companies, straight to your email.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals (NASDAQ:CDT), a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

View Conduit Pharmaceuticals Profile

More Earnings Resources from MarketBeat